Erythropoietin Resistance in Anemia of Chronic Kidney Disease

Duke University

Status: Completed

Conditions: Kidney Failure; Anemia; Erythropoietin

Study type: Observational

Funder types: Other

Identifiers

NCT00526747

Pro00008469

Details and patient eligibility

About

Our goal of this pilot project is to identify inflammatory biomarkers that correlate with epo-resistance among CKD patients.

Enrollment: 32 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• prevalent patients greater than or equal to 18 years old with CKD defined as a glomerular filtration rate < 60 cc/min

Exclusion criteria

• active GI bleeding or history of GI bleed in the prior 3 months
• uncontrolled hyperparathyroidism (PTH>500)
• untreated iron deficiency (transferrin saturation < 20% and ferritin < 100
• overt infection
• active hemolysis
• hemoglobinopathies
• known adverse response to erythropoietin
• prior kidney transplant
• aluminum toxicity

Trial design

32 participants in 2 patient groups

Epo-resistant

Description:

Patients with CKD (estimated GFR \< 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.

Epo-responsive

Description:

Patients with CKD (estimated GFR \< 60cc/min) not on hemodialysis who are requiring \<100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.